...
首页> 外文期刊>International Journal of Radiation Oncology, Biology, Physics >Current role of selective internal irradiation with yttrium-90 microspheres in the management of hepatocellular carcinoma: a systematic review.
【24h】

Current role of selective internal irradiation with yttrium-90 microspheres in the management of hepatocellular carcinoma: a systematic review.

机译:钇90微球选择性内部照射在肝细胞癌管理中的当前作用:系统综述。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: This article reviews the role of selective internal irradiation (SIR) with yttrium-90 ((90)Y) microspheres for hepatocellular carcinoma (HCC). METHODS AND MATERIALS: Studies were identified by searching Medline and PubMed databases for articles from 1990 to 2009 using the keywords "selective internal irradiation," "hepatocellular carcinoma," "therapeutic embolization," and yttrium-90. for unresectable HCC (median survival range, 7 -21.6 months). The evidence was limited to cohort studies and comparative studies with historical control. (90)Y microspheres have been reported to downstage unresectable HCC to allow for salvage treatments with curative intent, act as a bridging therapy before liver transplantation, and treat HCC with curative intent for patients who are not surgical candidates because of comorbidities. CONCLUSIONS: (90)Y microsphere is recommended as an option of palliative therapy for large or multifocal HCC without major portal vein invasion or extrahepatic spread. It can also be used for recurrent unresectable HCC, as a bridging therapy before liver transplantation, as a tumor downstaging treatment, and as a curative treatment for patients with associated comorbidities who are not candidates for surgery.
机译:目的:本文综述了使用钇90((90)Y)微球进行选择性内部照射(SIR)对肝细胞癌(HCC)的作用。方法和材料:通过检索Medline和PubMed数据库以检索1990年至2009年的文献,使用关键词“选择性内部照射”,“肝细胞癌”,“治疗性栓塞”和yttrium-90进行鉴定。用于不可切除的肝癌(中位生存期7 -21.6个月)。证据仅限于队列研究和具有历史对照的比较研究。 (90)Y微球据报道可以降低无法切除的HCC的水平,从而可以治愈性地进行挽救性治疗,在肝移植之前作为桥接疗法,并且对于因合并症而非手术候选人的患者,可以治愈性地对HCC进行治疗。结论:对于大型或多灶性肝癌,无主要门静脉侵犯或肝外扩散的患者,推荐使用(90)Y微球作为姑息治疗的选择。它也可以用于不可切除的HCC复发,肝移植前的桥接治疗,肿瘤分期治疗以及对合并症患者进行手术治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号